We proposed a novel deep learning-based method to predict the IDH1/2 mutation status in a glioma, even prior to IDH1 immunohistochemistry (which is typically performed using an antibody against the R132H mutation) and/or genetic sequencing. This evidence concerns the gene IDH1 and central nervous system cancer.